Equity Method Accounting for Common Stock of Oncocyte, at Fair Value (Tables)

6 Months Ended

Jun. 30, 2019

OncoCyte Corporation [Member]

Schedule of Equity Method Investments [Line Items]

Schedule of Condensed Results of Operations and Balance Sheet Information

OncoCyte’s unaudited condensed results of operations for the periods presented are summarized below (in thousands):

	Three Months Ended June 30, (unaudited)						Six Months Ended June 30, (unaudited)
	2019			2018			2019			2018
Condensed Statement of Operations:
Research and development expense	$	1,508		$	2,322		$	2,851		$	3,784
General and administrative expense		3,636			1,335			6,085			3,122
Sales and marketing expense		318			569			523			1,227
Loss from operations		(5,462	)		(4,226	)		(9,459	)		(8,133	)
Net loss	$	(5,384	)	$	(4,505	)	$	(9,248	)	$	(8,284	)